A61K 31/7072
Having two oxo groups directly attached to the pyrimidine ring
Official title: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K31/7072 (Having two oxo groups directly attached to the pyrimidine ring) appears on 1,100 US grants and 1,932 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,100
- Published applications
- 1,932
- Assignees
- 766
- Inventors
- 2,994
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 2 | 0 |
| 1989 | 5 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 3 | 0 |
| 1995 | 2 | 0 |
| 1996 | 5 | 0 |
| 1997 | 16 | 0 |
| 1998 | 19 | 0 |
| 1999 | 22 | 0 |
| 2000 | 17 | 0 |
| 2001 | 22 | 10 |
| 2002 | 17 | 37 |
| 2003 | 23 | 58 |
| 2004 | 10 | 69 |
| 2005 | 21 | 90 |
| 2006 | 31 | 103 |
| 2007 | 26 | 88 |
| 2008 | 20 | 48 |
| 2009 | 40 | 64 |
| 2010 | 41 | 57 |
| 2011 | 44 | 64 |
| 2012 | 45 | 47 |
| 2013 | 43 | 83 |
| 2014 | 61 | 131 |
| 2015 | 51 | 86 |
| 2016 | 55 | 120 |
| 2017 | 74 | 110 |
| 2018 | 55 | 95 |
| 2019 | 66 | 91 |
| 2020 | 57 | 79 |
| 2021 | 50 | 80 |
| 2022 | 25 | 88 |
| 2023 | 40 | 70 |
| 2024 | 33 | 65 |
| 2025 | 35 | 57 |
| 2026 | 23 | 42 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for X chromosome reactivation29 Sep 2026US 12,746,254 B2The Regents of the University of California
- Treatment of immunosuppressed subjects15 Sep 2026US 12,734,216 B2NantCell, Inc.
- Method for treating cancer patients with severe renal impairment8 Sep 2026US 12,728,130 B2Taiho Pharmaceutical Co., Ltd.
- Use of membrane inhibitors to enhance vaccine development against enveloped viruses8 Sep 2026US 12,728,161 B2Cornell University
- Synergistic nutritional compositions for treating vestibular associated neurodegenerative diseases18 Aug 2026US 12,708,640 B2Celagenex Research (India) Pvt. Ltd.
- Sulfurized imidazoles in ophthalmic formulations8 Oct 2026US 2026/0306457 A1Geneiii Biotech Company Ltd.
- Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs1 Oct 2026US 2026/0295040 A1Merus N.V.
- Mithramycin (mtm) 2’ oximes1 Oct 2026US 2026/0297121 A1University of Kentucky Research Foundation
- Methods for the synthesis of nucleoside analogues and nucleosides analogues derived therefrom1 Oct 2026US 2026/0297123 A1Simon Fraser University
- Composition for use for improving or preserving mental health in canine24 Sep 2026US 2026/0284093 A1Mars, Incorporated
Most cited
By later US patents
- Prodrugs phosphorus-containing compounds200US 6,312,662 B1Metabasis Therapeutics, Inc. · 2001
- Methods and compositions for treating flaviviruses and pestiviruses187US 7,105,493 B2Idenix Pharmaceuticals, Inc. · 2006
- 2′-Fluoronucleosides184US 6,348,587 B1Emory University · 2002
- Methods and compositions for treating hepatitis C virus173US 6,914,054 B2Idenix Pharmaceuticals, Inc. · 2005
- Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies166US 6,949,245 B1Genentech, Inc. · 2005